CeQur SA is touting preliminary results from study that evaluates long-term glycemic control produced by its wearable insulin delivery device.
CeQur SA, developer of a 3-day, wearable insulin delivery device, is touting promising preliminary results from a new study evaluating its glycemic control over three months.
The Horw, Switzerland-based company, said that early data from the trial shows its PaQ device consistently improved glycemic control in patients with type 2 diabetes. That conclusion comes from a single-arm treat-to-target 12-week pilot study involving eight people with the condition.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1LjqgtW
Cap comentari:
Publica un comentari a l'entrada